Eli Lilly reports Foundayo risk data: 30 analysts rate Eli Lilly stock

Published on 10/06/2026 at 11:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 22.97 billion, up 47.70 percent year over year. Eli Lilly stock costs EUR 1,021.40 on October 6, 2026 versus EUR 1,020.90.

Bauhaus-Poster mit geometrischen Formen und dem Wort PHARMA in Rot und Blau — Bauhaus-Poster mit geometrischen Formen repräsentiert Eli Lilly and Company, ISIN US5324571083, im Pharmasektor gestalterisch, Illustration mit AI erstellt.

Eli Lilly and Company (ISIN US5324571083) was trading at EUR 1,021.40 at Lang & Schwarz on October 6, 2026 at 11:06 a.m. CEST, up 0.05 percent versus the EUR 1,020.90 prior close. On October 1, 2026, Eli Lilly reported Foundayo data showing a predicted 57.00 percent reduction in 10-year type 2 diabetes risk at the 17.2 mg dose, while 30 analysts carried a Moderate Buy consensus for Eli Lilly stock.

Foundayo adds a measurable pipeline signal

The October 1 analysis covered the Phase 3 ATTAIN-1 study and separated modeled risk from observed disease outcomes. At 72 weeks, the 17.2 mg dose was associated with an estimated 18.00 percent reduction in predicted cardiovascular disease risk versus placebo, according to Eli Lilly.

The result extends the oral obesity-drug story, but it remains a modeled endpoint rather than a direct count of prevented diagnoses. That distinction matters as the company prepares to test commercial demand beyond injectable GLP-1 treatments.

EloraTZP beats Zepbound on weight loss

A second September 30, 2026 release showed the experimental EloraTZP combination produced average weight loss of up to 23.30 percent after 48 weeks, versus 14.80 percent for tirzepatide 15 mg alone. The Reuters report also noted treatment discontinuation rates of 10.80 percent to 27.00 percent for the combination, compared with 2.90 percent for tirzepatide alone.

Eli Lilly plans to begin Phase 3 testing of an EloraTZP co-formulation by the end of 2026. The comparison is commercially important because higher efficacy comes with a clear tolerability question during dose escalation.

Revenue growth meets a demanding valuation

For the second quarter of 2026, Eli Lilly reported revenue of USD 22.97 billion, up 47.70 percent from the same quarter a year earlier, according to MarketBeat. The next test is scheduled for October 29, 2026, when the company is due to report third-quarter results, according to TradingView.

MarketBeat lists 30 analyst ratings, including 25 Buy ratings, three Hold ratings, one Sell rating and one Strong Buy rating. Its average target is USD 1,311.96, while the finance quote places Eli Lilly's primary-market reference at USD 1,143.12 on October 5, 2026, a gap that leaves expectations sensitive to pipeline execution and pricing.

October 29 sets the next checkpoint

Eli Lilly's market capitalization was USD 1,076.5 billion as of October 5, 2026, while its 52-week range was USD 783.85 to USD 1,292.65. The Lang & Schwarz indication remained nearly unchanged against its prior close, leaving the October 29 report as the next dated test for revenue momentum and the obesity pipeline.

The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.